ArticlePediatric blood & cancer2021

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.

Holly J Meany et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.